Recent Advances in Tuberculosis Drug Development

M. Kotadiya, Olinirina Nisha Andriambololona
{"title":"Recent Advances in Tuberculosis Drug Development","authors":"M. Kotadiya, Olinirina Nisha Andriambololona","doi":"10.31838/ijprt/08.02.01","DOIUrl":null,"url":null,"abstract":"The emergence of drug-resistant tuberculosis is a growing disease worldwide. The lack of safe and effective drugs, together with the frequent development of adverse drug reactions could result in worse condition. Therefore, new drugs able to booster the current tuberculosis treatment regimen are urgently required. Novel drugs that are effective and safe against Mycobacterium tuberculosis are required to reduce the number of drugs and the duration of treatment in both drug-susceptible tuberculosis and multi-drug-resistant tuberculosis. Due to increased number of multidrugresistant and extensively drug-resistant strains and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in future. The scenario of drug discovery becomes upsetting when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the recent advances in anti-tubercular drug discovery, centre of attention on the research of compounds with potent anti-tuberculosis activity against multidrug-resistant tuberculosis strains. Although, the best treatment regimen for achieving better results and preventing adverse drug reactions remains yet to be determined, with safety concerns regarding cardiac events due to QT prolongation still to be addressed. Therefore a simple and short treatment with higher efficacy, and lesser adverse drug reactions and drug-drug interaction is expected for patients with multidrug-resistant and extensively drug-resistant tuberculosis.","PeriodicalId":225304,"journal":{"name":"International Journal of Pharmacy Research & Technology","volume":"352 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacy Research & Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31838/ijprt/08.02.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

The emergence of drug-resistant tuberculosis is a growing disease worldwide. The lack of safe and effective drugs, together with the frequent development of adverse drug reactions could result in worse condition. Therefore, new drugs able to booster the current tuberculosis treatment regimen are urgently required. Novel drugs that are effective and safe against Mycobacterium tuberculosis are required to reduce the number of drugs and the duration of treatment in both drug-susceptible tuberculosis and multi-drug-resistant tuberculosis. Due to increased number of multidrugresistant and extensively drug-resistant strains and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in future. The scenario of drug discovery becomes upsetting when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the recent advances in anti-tubercular drug discovery, centre of attention on the research of compounds with potent anti-tuberculosis activity against multidrug-resistant tuberculosis strains. Although, the best treatment regimen for achieving better results and preventing adverse drug reactions remains yet to be determined, with safety concerns regarding cardiac events due to QT prolongation still to be addressed. Therefore a simple and short treatment with higher efficacy, and lesser adverse drug reactions and drug-drug interaction is expected for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
结核病药物开发的最新进展
耐药结核病的出现在全世界是一种日益严重的疾病。缺乏安全有效的药物,加上药物不良反应的频繁发生,可能导致病情恶化。因此,迫切需要能够加强当前结核病治疗方案的新药。为了减少药物敏感结核病和耐多药结核病的药物数量和治疗时间,需要有效和安全的抗结核分枝杆菌新药。由于耐多药和广泛耐药菌株数量的增加以及目前治疗潜伏性结核病的有效性是未来需要克服的挑战。当考虑到新药的数量并没有随着耐药性的出现而成比例地增加时,药物发现的情况就变得令人沮丧。本文综述了近年来抗结核药物的研究进展,重点介绍了对耐多药结核菌株具有有效抗结核活性的化合物的研究。尽管如此,获得更好结果和预防药物不良反应的最佳治疗方案仍有待确定,QT间期延长引起的心脏事件的安全性问题仍有待解决。因此,多药耐药和广泛耐药结核病患者的治疗方法简单、时间短、疗效高、药物不良反应少、药物相互作用少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信